@ascletisp
ID: 1589465332758052864
calendar_today07-11-2022 03:51:52
124 Tweet
14 Takipçi
0 Takip Edilen
a year ago
Hong Kong, China, Sep 17, 2024 – Ascletis Pharma Inc. (HKEX:1672)announces the completion of initial dosing in its two recently initiated U.S. Phase I clinical trials for ASC30. ascletis.com/news_detail/18…